2BKK image
Deposition Date 2005-02-16
Release Date 2005-08-09
Last Version Date 2023-12-13
Entry Detail
PDB ID:
2BKK
Title:
Crystal structure of Aminoglycoside Phosphotransferase APH(3')-IIIa in complex with the inhibitor AR_3a
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.15 Å
R-Value Free:
0.26
R-Value Work:
0.19
R-Value Observed:
0.20
Space Group:
P 1 21 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:AMINOGLYCOSIDE 3'-PHOSPHOTRANSFERASE
Mutagens:YES
Chain IDs:A, C
Chain Length:264
Number of Molecules:2
Biological Source:ENTEROCOCCUS FAECALIS
Polymer Type:polypeptide(L)
Molecule:DESIGNED ANKYRIN REPEAT INHIBITOR AR_3A
Chain IDs:B, D
Chain Length:169
Number of Molecules:2
Biological Source:SYNTHETIC CONSTRUCT
Primary Citation
Allosteric Inhibition of Aminoglycoside Phosphotransferase by a Designed Ankyrin Repeat Protein
Structure 13 1131 ? (2005)
PMID: 16084385 DOI: 10.1016/J.STR.2005.04.020

Abstact

Aminoglycoside phosphotransferase (3')-IIIa (APH) is a bacterial kinase that confers antibiotic resistance to many pathogenic bacteria and shares structural homology with eukaryotic protein kinases. We report here the crystal structure of APH, trapped in an inactive conformation by a tailor-made inhibitory ankyrin repeat (AR) protein, at 2.15 A resolution. The inhibitor was selected from a combinatorial library of designed AR proteins. The AR protein binds the C-terminal lobe of APH and thereby stabilizes three alpha helices, which are necessary for substrate binding, in a significantly displaced conformation. BIAcore analysis and kinetic enzyme inhibition experiments are consistent with the proposed allosteric inhibition mechanism. In contrast to most small-molecule kinase inhibitors, the AR proteins are not restricted to active site binding, allowing for higher specificity. Inactive conformations of pharmaceutically relevant enzymes, as can be elucidated with the approach presented here, represent powerful starting points for rational drug design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback